ROS1 rearrangement coexists with EGFR mutation in non-small-cell lung cancer.

e19003 Background: C-ros oncogene 1 receptor tyrosine kinase (ROS1) is a newly identified gene-rearranged oncogenic receptor tyrosine kinase and patients seem to benefit from crizotinib treatment. We aim to evaluate the clinical characteristics and molecular profile of ROS1-rearranged patients with non-small-cell lung cancer (NSCLC). Methods: Between December 2013 and December 2014, we screened 708 NSCLC patients using reverse transcription Polymerase Chain Reaction (RT-PCR) assay and correlated ROS1 rearrangement status with clinical features. EGFR mutation was detected by DNA sequencing or ARMS. KRAS mutation and ALKrearrangement were tested by DNA sequencing and FISH respectively. Results: Of 708 NSCLC patients, ROS1 rearrangements were detected in 11 cases (1.6%).There was no significant difference in age (P= 0.74), gender (P= 0.54), stage (I-IIIA vs. IIIB-IV P= 0.74), histology (adenocarcinoma vs non-adenocarcinoma, P= 0.99) or T status (T0-2 vs. T3-4, P= 0.23) between patients with ROS positive and ...